June 11 (Reuters) – Johnson & Johnson’s Stelara
produced significant improvement in signs and symptoms of
psoriatic arthritis through 52 weeks of treatment in a late
stage study, according to data being presented at a medical
meeting in Europe.
The Phase III trial tested Stelara at two doses against a
placebo in 312 patients with active psoriatic arthritis, and
included both subjects who had previously been treated with
widely used biotech drugs from a class known as anti-TNF
medicines and those who had not.
(Reuters) – Forest Laboratories Inc is trying to avert yet another bitter proxy battle with billionaire investor Carl Icahn ahead of its annual investor meeting this summer, according to two sources familiar with the situation.
Icahn, Forest’s second-largest shareholder, and the company have been in discussions over the course of the year and talks are ongoing to avoid a third proxy fight in as many years, the sources said.
June 2 (Reuters) – The widely used Roche Holding AG
cancer drug Avastin failed to prolong survival when added to
chemo-radiation therapy for glioblastoma – a fast-growing type
of brain tumor – according to data presented on Sunday.
Those who received Avastin in the late-stage study of 637
previously untreated patients also experienced more side
effects, such as low platelet counts, blood clots and elevated
blood pressure. Researchers said the toxicity was not severe
enough to preclude use of Avastin, or bevacizumab, had it helped
patients live longer.
June 2 (Reuters) – Roche Holding AG’s drug Avastin
helped prolong the lives of women with advanced cervical cancer
when added to chemotherapy in a late-stage clinical trial,
likely paving the way to another major use for the
This marked the first study to demonstrate that a drug which
blocks blood vessel formation in the tumor can prolong the lives
of women with gynecologic cancers, researchers said.
LONDON/NEW YORK (Reuters) – U.S. health regulators have approved two new GlaxoSmithKline drugs for treating advanced melanoma, in the latest sign that companies are having more success getting novel medicines to market.
The Food and Drug Administration (FDA) gave the green light to Tafinlar and Mekinist late on Wednesday, bringing the tally of new drugs approved by the U.S. agency so far this year to 13, compared with 11 at the same stage in 2012.
NEW YORK, May 27 (Reuters) – Americans accustomed to
immediate access to the newest technology may be shocked to find
that is not the case when it comes to devices that treat ailing
U.S. approval requirements for cardiac devices are much more
stringent than in Europe, where there is no centralized
decision-making body. But a growing number of U.S. heart doctors
feel the regulations are so demanding that patients are being
denied access to beneficial therapies.
By Bill Berkrot
(Reuters) – First Manhattan Company (FMC) added some heavyweight muscle on Thursday to its bid to shake up the board of drugmaker Vivus Inc (VVUS.O: Quote, Profile, Research, Stock Buzz) by naming former Carl Icahn top lieutenant Alex Denner and two others to its slate of proposed nominees.
Vivus shares rose as much as 11 percent after First Manhattan, which has nearly a 10 percent stake in Vivus, expanded its slate of proposed directors from six to nine, including Denner.
NEW YORK (Reuters) – Little known biotechnology company Merrimack Pharmaceuticals Inc has quietly built a large pipeline of experimental cancer treatments that it aims to deliver at a fraction of the cost spent by larger rivals.
That could translate into lower-cost treatments for large unmet needs, such as pancreatic cancer, at precisely the time when pressure is mounting to reduce runaway healthcare spending.
By Bill Berkrot
(Reuters) – An experimental leukemia treatment that Roche Holding AG hopes will improve upon its best-selling cancer drug Rituxan delayed disease progression twice as long as chemotherapy, according to preliminary trial data released on Wednesday.
Switzerland-based Roche aims to fend off cheaper competition for Rituxan, which loses patent protection in Europe later this year, threatening a product with nearly $7 billion in annual sales.
May 15 (Reuters) – An experimental Roche Holding AG
drug that helps the immune system attack tumors was well
tolerated and demonstrated an impressive effect against a
variety of cancers, according to preliminary trial results
released on Wednesday.
While clinical testing of the drug is still in its early
phases, the Roche treatment is considered one of the most
promising in a new class of immunotherapies being developed by